CD8A and neoplasm: Additionally, another phase II trial with 93 patients who had previously been treated for metastatic PDAC revealed that incorporating nivolumab into the CRS-207/cyclophosphamide/GVAX regimen restructured the tumor microenvironment by increasing CD8+ T-cell proliferation and decreasing TAM and myeloid cell populations.